Rapid Antigen Deployment (RAD) process enabling fast generation of protein subunit vaccine antigens and monoclonal antibodies for pathogens including SARS‑CoV‑2, Dengue, Zika, West Nile and Japanese encephalitis. Partners with biopharmaceutical firms to supply single‑vaccine licenses, access to antigen inventories, and prioritized commercial development access.